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metastases 2 months after treatment. Secondly, we report a 79-year-old man with an ulcer in the left ear. It was excised. Pathology
showed EP with close surgical margin; it was widened. Workup showed no distant metastases. In February 2010 conformational
3-D RT was administered (30 sessions). Treatment volumes: PTV1:tumor bed (TD: 60Gy); PTV2(TD: 54): left preauricular and
cervical lymph node levels II–III. PTV1 was treated with a direct ﬁeld (6MeV electrons). The patient had acute toxicity: RTOG G1
dermatitis and alopecia and is in complete remission (2-year follow-up).
Conclusions. EP diagnosis and management is difﬁcult. Optimal treatment remains unknown. Early diagnosis and wide local
excision show best results. Adjuvant RT can help achieve local control in EP with adverse factors, and in local and locoregional
recurrences.
http://dx.doi.org/10.1016/j.rpor.2013.03.566
Eccrine syringomatous carcinoma of the skin
M. Casasús Farré1, C. Nicolau Martorell 1, F. Mestre Mestre1, H. Giosefﬁ2
1 Instituto Oncológico Policlínica Miramar, Oncología Radioterápica, Spain
2 Instituto Oncológico Policlínica Miramar, Oncología Médica, Spain
Introduction. Syringomatous carcinoma (SC) is a rare cutaneous neoplasm, located more often on the face and on the scalp.
Histologically it is characterised by an inﬁltrative pattern of basaloid or squamous cells, with a desmoplastic stromal reaction
and keratin ﬁlled cysts, and with granular structures.
Objectives. We present a case report of SC and a review of the literature.
Method. A 75-year-old woman with an ulcerative interciliar lesion measuring 2 cm×3 cm. After resection, the histological and
immunohistochemical examinations pointed to the diagnosis of an eccrine SC, poorly differentiated, with positive margins
and with perineural and underlying bone invasion. In November 2011, the patient was treated with adjuvant radiotherapy over
the tumor bed, up to a total dose of 60Gy in 2Gy daily fractions. We have reviewed Pubmed articles found using the terms
“syringomatous carcinoma”, selecting those related to face location.
Results. One year after the treatment with local radiotherapy was ﬁnished, there is no evidence of locoregional relapse and the
patient relied in good status.
Conclusions. Although SC is apparently benign, it is extremely invasive and locally destructive. Its growth’s rate is slow. It is an
adnexal tumour, derived from eccrine sweat glands. It is often mistaken, both clinically and microscopically, for other benign
and malignant entities. The tumour recurrence is high due to extensive perineural invasion, but regional or distant metastases
are rare. Because of the local aggressiveness of the tumour, the optimal treatment is the complete surgical excision with negative
margins at microscopic level. Post-operative local radiation therapy is recommended when there are poor histological prognosis
factors.
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Introduction. Radiotherapy has been demonstrated useful and safe in non-melanoma skin cancer, with a good local control and
few adverse effects. Although, surgery still remains the standard treatment, some facial areas have surgical technical limitations,
tumor-free margins often means reconstructive surgery and poor cosmetic outcomes. At this setting, superﬁcial radiotherapy
(sRT) plays a signiﬁcant relevance. We collected the outcomes of patients treated (with curative intent) in our department with
a hypofractionated schedule in sRT for facial basal cell carcinoma.
Materials and methods. A total of 87 patients were diagnosed of basal cell carcinoma between 2009 and 2011 and treated with a
100kV orthovoltage X-rays unit and a hypofractionated schedule. A total dose of 3960 cGy in 9 fractions of 440 cGy, tree times
per week. Therapy was delivered by the same radiotherapy technician and visited by a nurse. At the beginning and during the
treatment the patients were visited by a physician to control a safety margin of 5–10mm and acute toxicity, then the surveillance
was done every 3 months during the ﬁrst year and after that once a year.
Results. All of patients but one completed therapy. Acute toxicity >grade 2 was seeing in 21 patients and forced to stop temporarily
the treatment. The median time of interruption treatment was 1 week. The mean size was 1.9 cm (size median 1.5 cm). The most
frequent localization was the nose 81%. Bad cosmetics outcomes were not reported. Local control was 95.5%. Three patients
relapsed at the irradiated area (mean time of progression was 14 months) and one was a non-responder.
Conclusion. Orthovoltage hypofractionated schedule is a well tolerated treatment option in facial basal cell carcinoma with lower
ﬁnancial costs, good local control and competitive cosmetic outcomes.
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